Regenerative failure at barrier surfaces and maladaptive repair leading to fibrosis are hallmarks of graft-versus-host disease (GVHD). Although immunosuppressive treatment can control inflammation, impaired tissue homeostasis leads to prolonged organ damage and impaired quality of life. In this Blood Spotlight, we review recent research that addresses the critical failures in tissue regeneration and repair that underpin treatment-resistant GVHD. We highlight current interventions designed to overcome these defects and provide our assessment of the future therapeutic landscape.

Graft-versus-host disease (GVHD) remains a major barrier to successful allogeneic hematopoietic stem cell transplantation.1,2 Unfortunately, current therapies for GVHD lack precision and rely upon inducing global immune suppression, which contributes to high rates of nonrelapse mortality secondary to infection and an increased risk of blood cancer relapse.1,2 Furthermore, treatment resistance is common and emerges quickly during disease evolution. The recent introduction of JAK1/2 inhibitors still fails to serve as salvage therapy for a significant proportion of patients,3,4 suggestsing that some tissue damage is irreversible. Indeed, disease progression in the face of profound immune deficiency argues that mechanisms other than the magnitude of the alloimmune response are important in influencing the trajectory of GVHD. Wu and Reddy 5 recently proposed a conceptual framework for GVHD pathogenesis in which the structural cells of peripheral tissues play a critical role in regulating the disease course, either through counterregulatory responses to inflammation (immune tolerance)6,7 or through intrinsic properties that allow them to withstand the combined effects of conditioning-induced and immune-related injury (tissue tolerance).5 Although cellular resistance to apoptosis8,9 can confer some components of tolerance, restoration of tissue homeostasis ultimately relies upon regeneration and repair. Healing is normally orchestrated by highly conserved mechanisms involving self-limited activation of the innate immune system (eg, via cytokines such as interleukin-6 [IL-6], tumor necrosis factor α [TNF-α], and signaling pathways, such as NF-κB)10,11; however, an early failure to curtail inflammation as a result of adaptive immune reactivity directly interferes with the processes of regeneration and repair in GVHD (Figure 1). In this Blood Spotlight, we summarize recent data demonstrating how GVHD and its treatment disrupt healing and discuss how this information might be used to develop new targeted therapies.

Figure 1.

Impact of GVHD on tissue regeneration and repair mechanisms. Tissue responses in steady state and/or the response to acute sterile injury (A, C, E) are compared with those observed during GVHD (B, D, F) for the intestine (A, B), thymus (C, D), and skin/lung (E, F). AhR, aryl hydrocarbon receptor; APC, antigen presenting cell; AREG, amphiregulin; BMP-4, bone morphogenetic protein 4; CM, corticomedullary; cTEC, cortical thymic epithelial cell; DAMP, damage-associated molecular pattern; DC, dendritic cell; DLL4, delta-like ligand 4; DP, double positive; EGF, epidermal growth factor; FcR, Fc receptor; FGF, fibroblast growth factor; GC, germinal center; GLP-2, glucagon-like peptide 2 (note was defined in text); Hsp47, heat shock protein 47; IFN-γ, interferon-γ; IGF-1, insulin-like growth factor 1; ILC, innate lymphoid cell; ISC, intestinal stem cell; KGF, keratinocyte growth factor; LEC, lymphatic endothelial cell; Mac, macrophage; mo, monocyte; mTEC, medullary thymic epithelial cell; PAMP, pathogen-associated molecular pattern; RANKL, receptor activator of NF-κΒ ligand; SP, single positive; Teff, effector T cell; TEPC, thymic epithelial progenitor cell; Tfh, follicular helper T cell; TGF-α/β, transforming growth factor-α/β; Th17, T helper 17 cell; Treg, regulatory T cell; VEGF, vascular endothelial growth factor; WNT, wingless-related integration site.

Figure 1.

Impact of GVHD on tissue regeneration and repair mechanisms. Tissue responses in steady state and/or the response to acute sterile injury (A, C, E) are compared with those observed during GVHD (B, D, F) for the intestine (A, B), thymus (C, D), and skin/lung (E, F). AhR, aryl hydrocarbon receptor; APC, antigen presenting cell; AREG, amphiregulin; BMP-4, bone morphogenetic protein 4; CM, corticomedullary; cTEC, cortical thymic epithelial cell; DAMP, damage-associated molecular pattern; DC, dendritic cell; DLL4, delta-like ligand 4; DP, double positive; EGF, epidermal growth factor; FcR, Fc receptor; FGF, fibroblast growth factor; GC, germinal center; GLP-2, glucagon-like peptide 2 (note was defined in text); Hsp47, heat shock protein 47; IFN-γ, interferon-γ; IGF-1, insulin-like growth factor 1; ILC, innate lymphoid cell; ISC, intestinal stem cell; KGF, keratinocyte growth factor; LEC, lymphatic endothelial cell; Mac, macrophage; mo, monocyte; mTEC, medullary thymic epithelial cell; PAMP, pathogen-associated molecular pattern; RANKL, receptor activator of NF-κΒ ligand; SP, single positive; Teff, effector T cell; TEPC, thymic epithelial progenitor cell; Tfh, follicular helper T cell; TGF-α/β, transforming growth factor-α/β; Th17, T helper 17 cell; Treg, regulatory T cell; VEGF, vascular endothelial growth factor; WNT, wingless-related integration site.

Close modal

To maintain tissue homeostasis, the epithelia of the intestine and the skin are characterized by very high rates of cell turnover in the steady state.12 The demands of rapid cell turnover are met by the immense regenerative capacity of tissue-resident adult stem cell populations.11 When stressed by acute, sterile injury (eg, a genotoxic insult such as irradiation), re-epithelialization is conducted by both surviving stem cells and by more committed progenitor cells in the vicinity (eg, transit-amplifying cells [TACs] within crypt-proximal regions or zones of the villus and lower segment hair follicle cells), the latter responding to wingless-related integration site (WNT)-driven signals by dedifferentiating to stem cell–like cells.13,14 Although this plasticity is important in allowing early recovery after time-limited insults, the decline in regenerative capacity associated with aging indicates that stem cell reserve can be finite and may not be sustainable over the long term.14 In GVHD, the immune sensitivity of resident stem cells15,16 combined with the derangement of stem cell–supportive niches17 drastically reduces the capacity for regeneration (Figure 1A-B). Indeed, shortened enterocyte telomeres in biopsies from patients with the most severe forms of intestinal GVHD suggest excessive proliferation and eventual exhaustion of the stem cell pool.18 

Histologically, acute GVHD (aGVHD) is characterized by the presence of apoptotic cells spatially restricted to sites that harbor stem cells at the base of the intestinal crypts19 or in the hair follicle bulge or rete ridges of the skin20,21; apoptosis is associated with intestinal crypt drop out,22 or impaired progression to hair follicle growth and wound healing.15 In preclinical models of aGVHD, donor T cells are found in close proximity to Lgr5+ stem cells of the intestinal crypts23,24 and of the bulge region of the hair follicle.15 Although quiescent tissue-resident stem cells can avoid being targeted by T cells through downregulation of the expression of surface major histocompatibility complex molecules, stem cells entering the cell cycle (eg, in response to irradiation25) and/or responding to local microbiota24 upregulate major histocompatibility complex molecules thereby increasing their sensitivity to immune attack.

Erosion of epithelial stem cell reserve in GVHD is further reinforced by disruption to local epithelial-stromal-immune microenvironments that normally operate to protect tissue stem cells and TACs; so far, these concepts have been explored mostly for the intestine.26 In irradiation-induced injury, both innate immune populations (myeloid and innate lymphoid cells [ILCs]) and regulatory T cells (Tregs) provide one tier of protection for intestinal stem cells (ISCs).11 For example, tissue recruitment of myeloid cells that secrete IL-23 triggers local RORγt+ ILC3 populations to generate local IL-22, which then acts directly on ISCs or TACs to prevent apoptosis via a STAT3-dependent mechanism.27 In addition, GATA3+ ILC2 populations produce IL-13, which maintains ISC survival via a FOXP1-β-catenin–dependent pathway28 and promotes goblet cell differentiation.29 Tregs also secrete trophic factors (eg, IL-10) that promote ISC expansion, while countering stem cell exhaustion from excessive differentiation.30 These normally protective immune populations are either outcompeted or depleted during GVHD, as manifested by the absence of ILCs27,31 and the relative deficiency of regulatory T cells (Tregs) within affected tissues.

The reaction of the intestinal epithelial compartment to immune injury has an important role in shaping the trajectory of GVHD. Although cause and effect are difficult to distinguish in vivo, T-cell reactivity in intestinal organoid cultures in vitro enriches for short-lived progeny and sculpts the repertoire of differentiated cells that emerge. In the case of T helper 17 (Th17) cells, the shift is heavily toward enterocyte differentiation with loss of more specialized populations.30 

This process of immune editing and loss of specialized intestinal cell populations deprives ISCs of important niche-supporting functions. For example, loss of Paneth cells deprives the ISCs of factors such as epidermal growth factor (EGF), transforming growth factor α (TGF-α), WNT3, and delta-like ligand 4 (DLL4), which are essential for their maintenance.17,33 Similarly, loss of entero-endocrine L cells depletes glucagon-like peptide 2 (GLP-2), which normally promotes the regeneration of ISCs and Paneth cells. Indeed, the GLP2 agonist teduglutide prevents apoptosis in intestinal organoids in vitro and diminishes experimental GVHD in vivo.34 Further reductions in epithelial integrity arise through the loss of the goblet cell–derived protective intraluminal mucous layer29 and through gut dysbiosis, which occurs when anti-microbial peptides derived from Paneth cells are depleted.35 GVHD also interferes with ISC-stromal interactions, by depriving stem cells of niche factors that promote their survival. For example, in the steady state, R-spondins promote self-renewal of Lgr5+ ISCs through a process that requires priming by WNT family proteins.36 In GVHD, R-spondin production from intestinal lymphatic endothelial cells is impaired,37 and exogenous replacement of R-spondin protects ISCs in experimental stem cell transplantation.16,35 Remodeling of the mesenchyme may also deprive ILC3 populations of the IL-7 required for their survival.38 

Large registry studies39,40 support the concept that increasing conditioning intensity (especially through total body irradiation) is linked to higher rates of aGVHD, although randomized clinical trials comparing protocols with different cytoreductive potential have provided variable data.41 Experimentally, conditioning-induced injury lowers the threshold for the induction of aGVHD7 and also counters restoration of tissue homeostasis through several mechanisms. For example, reduced enteral nutrition in the early phase of transplantation decreases transepithelial resistance, which allows submucosal migration of bacteria (reviewed in Schörghuber and Fruhwald42). Depriving enterocytes of luminal nutrients directly blunts their metabolic activity (eg, reducing Akt phosphorylation), which leads to loss of villous structure and reduces crypt depth.43 Parenteral nutrition further promotes an imbalance between damaging (TNF-α) and protective cytokines (EGF, IL-10) leading to increased enterocyte apoptosis and impaired tight junction integrity.44-47 Although these preclinical and some correlative clinical data support the concept that enteral nutrition mitigates against GVHD,48 this question is being formally evaluated in the NEPHA randomized controlled trial, which recently completed recruitment.49 

Both parenteral nutrition and use of broad-spectrum antibiotics during the neutropenic phase after transplant cause major distortions in the intestinal microflora, which reduces diversity and selects for pathogenic micro-organisms; the altered microflora can damage the protective mucus layer, create an unfavorable local metabolome, or prevent healing (reviewed extensively in Rafei and Jenq48 and Fredricks50). The precise composition of microbial-derived metabolites that favor intestinal epithelial regeneration is not fully known and is likely to be context dependent. Short-chain fatty acids are the main metabolites produced by the intestinal microbiota, and they regulate intestinal homeostasis and the immune system. For example, butyrate-producing bacteria (eg, Clostridia species) provide mature enterocytes with an essential energy source that is required for the maintenance of the villous structure and inter-epithelial cell tight junctions.51 Both the physical barrier of the villi and the active oxidation of butyrate by enterocytes reduce exposure of ISCs to butyrate at the base of the crypts, where it has a paradoxical Foxo3-dependent inhibitory effect upon proliferation.52 Thus, although exogenous butyrate has been demonstrated to prevent experimental GVHD,51 it also impairs intestinal epithelial regeneration in established experimental colitis in which villous structure has already been lost52; this latter possibility is supported by preliminary clinical data in patients with refractory intestinal GVHD in which butyrogenic bacteria are more prominent.53 A recent study in inflammatory bowel disease has suggested that antibiotic use can deplete commensal bacteria (eg, Akkermansia mucophilia54) that normally colonize intestinal ulcers and promote wound healing; instead, ulcers were colonized by the yeast Debaryomyces hansenii, which promotes a macrophage type I interferon response that directly antagonizes re-epithelialization.55 

Therapies used to arrest the inflammatory response may also have an unintended adverse impact on healing. Although glucocorticoids can protect against epithelial injury by inhibiting TNF-α–induced necroptosis56 and promoting tight junction integrity,57 they also impair the generation of IL-22 by ILC358 and decrease epithelial proliferation and migration.59 Long-term use of topical corticosteroids induces skin atrophy and delayed wound healing by inhibiting keratinocyte proliferation, a process that may be underpinned by corticosteroid-induced loss of Lgr5+ hair follicle stem cell.15 In contrast, the benefit of ruxolitinib in glucocorticoid-resistant aGVHD may derive from its better preservation of adult stem cells in the skin15 and gut,60 the latter effect through direct prevention of JAK1-dependent ISC apoptosis.60 The capacity of other immune suppressive drugs to regulate epithelial regeneration in GVHD has not been addressed, but it is likely to be complex. For example, NFAT (targeted by calcineurin inhibitors) and mTORC1 (targeted by rapamycin) seem to have opposing effects on telogen-to-anagen transition of the hair follicle.61,62 Furthermore, although adult stem cells require restrained mTORC1 activity to maintain the capacity for self-renewal and differentiation in the gut, progenitor cells elevate mTORC1 activity to support their expansion and differentiation.63 

After acute injury, the specialized stroma of the thymus,64,65 lymph node,66 and bone marrow67 is normally capable of rapid regeneration in younger individuals. The recovery process at each site involves an intricate dialog between stromal precursors and cells derived from bone marrow.64-67 In irradiation-induced thymic injury, a complex array of trophic factors produced by thymic endothelia (BMP-468), ILC3 (IL-22,69 receptor activator of NF-κΒ ligand69,70), and thymocytes (keratinocyte growth factor [KGF],71 lymphotoxin72) coalesce in driving Foxn1 upregulation in thymic epithelial precursors,64 thus promoting their proliferation and restoration of the damaged epithelial structure (Figure 1C-D). In the bone marrow, irradiation triggers a transient reduction in stromal population complexity,73 whereas stroma that support the hematopoietic stem cell niche are preserved through interactions with resident immune cells (macrophages74 and Tregs75) and cross-talk with incoming hematopoietic progenitors.76 In a process that mirrors the development of the lymph node analgen, regeneration of lymph node structure after hypoxia or infection requires cooperation between IL-7+ stroma77 and lymphotoxin+ ILC3-like lymphoid tissue inducer cells.78 These regenerative programs are impeded by GVHD as manifested by permanent derangement of lymphoid organ stromal architecture, for example, in the loss of medullary thymic epithelial cells (mTECs),79 lymph node fibroblastic reticular cells (FRCs),80,81 and bone marrow perisinusoidal mesenchymal stromal cells82 and osteoblasts.83 In thymic GVHD, recovery of thymic epithelia is impaired by parallel loss of host-derived intrathymic ILC3 populations, which leads to depletion of the IL-22 normally required for stromal regeneration.84 Physiological, age-related degeneration of the thymic stroma (eg, reduced Foxn1 expression in aged TECs85), may increase sensitivity to immune injury and explain the poor recovery of thymic function in older patients who develop aGVHD.86 In other lymphoid organs, the mechanisms that underpin regenerative failure remain unclear. For example, although depletion of host ILC3-like lymphoid tissue inducer cells also occurs in lymph node GVHD, this population is redundant in protecting the FRC network from alloimmune injury.80 Thus, there is an important need to systematically interrogate how stromal progenitors and other interacting cell populations are affected by GVHD. Extrapolation to the human setting will also require an evaluation of the impact of drugs routinely used in transplantation, such as calcineurin inhibitors and glucocorticoids that deplete mTECs87 and CD4+ T-cell immunodepletion, which impairs the FRC network integrity.88 

In most patients, chronic GVHD (cGVHD) emerges after previous development of aGVHD,2 an observation consistent with a model in which early injury is critical to the subsequent development of fibrosis. After wounding, monocytes recruited from the circulation and tissue-resident macrophages play critical roles in the transition from acute inflammation toward a pro-resolution tissue repair mode.89 In this tightly regulated process, timely reimposition of the anti-inflammatory epigenetic programs of tissue-resident macrophages (including those derived from differentiating monocytes) normally enables restoration of tissue integrity while limiting fibroblasia and scarring90 (Figure 1E-F). In preclinical models of sclerodermatous GVHD91-93 and bronchiolitis obliterans,94 this reset does not occur. Instead, local pro-inflammatory cell circuits imprint a pathogenic differentiation program upon incoming monocytes that leads to macrophage accumulation and remodeling of the mesenchyme and extracellular matrix toward a fibrotic trajectory.95 Although the phenotype of fibrogenic macrophages in GVHD conforms to alternatively activated M2-like cells,91 data from other models of fibrosis suggest that such populations are likely to be heterogeneous, with different roles according to location, cell–cell interactions, and time from insult.90,96 Via generation of transforming growth factor β1 (TGF-β1), profibrogenic macrophages have the potential to induce myofibroblast differentiation from multiple cell types (eg, from tissue fibroblasts or pericytes or through epithelial-to-mesenchymal or endothelial-to-mesenchymal transition).96 In skin and ocular cGVHD, the increased expression of the pro-collagen chaperone heat shock protein 47 (Hsp47) is a targetable molecular marker of pathogenic myofibroblast differentiation.93,97 profibrogenic transcriptional programs in myofibroblasts are reinforced by extracellular matrix mechanical cues that trigger integrin-mediated activation of latent TGF-β198 or by cell-cell interactions involving developmental morphogens such as those involved in WNT activation.99 Dynamic models of tissue fibrosis suggest that rapid increases in macrophage and myofibroblast frequencies positively reinforce each other, reaching an early tipping point that antagonizes return to the steady state.100 The failure of this macrophage-myofibroblast cell circuit feed-forward loop to dissipate is complex, but the major amplifiers in murine models are pro-inflammatory Th17-lineage cells that through secretion of CSF-1 drive monocyte recruitment from the circulation.91 Further amplification of this circuit may also be mediated by other cells and cytokines, for example by the in situ effects of IL-21 produced by follicular helper T cell.92 By promoting abnormal germinal center formation,101 follicular helper T cell may also drive auto- or allo-immunoglobulin G antibody formation and accelerate the fibrotic process through Fc receptor-mediated macrophage activation.95 

Most current and investigational treatments for GVHD focus on interrupting inflammatory pathways, but their major disadvantage is that they also exacerbate immune deficiency. Alternative strategies that instead promote tissue tolerance through regeneration and repair are therefore attractive (summarized in Table 1). However, there are several challenges to be overcome before the preclinical findings can be readily translated to the clinic. First, precise upregulation of regeneration and repair pathways may be difficult because of significant overlap with those involved in resolving and/or amplifying inflammation. For example, although IL-22 has epithelial protective effects,27,69 IL-22 produced by pro-inflammatory donor Th22 and Tc22 cells have deleterious effects in the intestine102 and skin.103 Second, some of the key players involved in regeneration and repair have divergent effects according to their spatial (eg, macrophages90) or their temporal context (eg, TGF-β1, protective in early GVHD104). Third, on-target toxicities are likely to be important, for example because myofibroblast-targeted therapies may also impair normal wound healing.105 Finally, the complexity and redundancy of certain pathways (eg, Wnt-Frizzled-β-catenin) has previously been a disincentive to pursuing a targeting strategy by the biopharmaceutical sector, although this pinch point may be changing with better molecular resolution of their actions and regulation.106 

There is an important need to address in more detail how GVHD affects tissue regeneration and repair. In particular, preclinical modeling should seek to separate the direct effects of immune injury from mechanisms that underpin tissue tolerance , including the capacity for tissues to recover when the initial immune insult is arrested. These data will provide new information regarding the regenerative and repair gap to be addressed by less immune suppressive interventions. In the clinic, novel targets could be prioritized through cross-disciplinary interactions with other fields in which disruption to regenerative or repair programs share common cellular and molecular mechanisms (which would allow testing in bucket trials, such as trials in systemic sclerosis in which a huge panoply of investigational drugs is being tested105). Adaptive trial designs that focus on common cellular and molecular mechanisms that incorporate surrogate biological end points to allow rapid selection of novel therapies could greatly accelerate advances in this area.

Contribution: R.C. and T.T. conceived and co-wrote the article.

Conflict-of-interest disclosure: R.C. received speaking honoraria from Neovii and Mallinckrodt Pharmaceuticals (Therakos) and received consultancy fees from Novartis. T.T. has received personal fees from Merck Sharp & Dohme, Takeda, Pfizer, and Bristol-Myers Squibb, grants from Chugai, Sanofi, Astellas, Teijin Pharma, Fuji Pharma, and Nippon Shinyaku, grants and personal fees from Kyowa Kirin, grants and personal fees and non-financial support from Novartis, and non-financial support from Janssen.

Correspondence: Ronjon Chakraverty, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom; e-mail: ronjon.chakraverty@ndcls.ox.ac.uk.

1.
Zeiser
R
,
Blazar
BR.
Acute graft-versus-host disease – biologic process, prevention, and therapy
.
N Engl J Med.
2017
;
377
(
22
):
2167
-
2179
.
2.
Zeiser
R
,
Blazar
BR.
Pathophysiology of chronic graft-versus-host disease and therapeutic targets
.
N Engl J Med.
2017
;
377
(
26
):
2565
-
2579
.
3.
Zeiser
R
,
Polverelli
N
,
Ram
R
, et al;
REACH3 Investigators
.
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
.
N Engl J Med.
2021
;
385
(
3
):
228
-
238
.
4.
Zeiser
R
,
von Bubnoff
N
,
Butler
J
, et al;
REACH2 Trial Group
.
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
.
N Engl J Med.
2020
;
382
(
19
):
1800
-
1810
.
5.
Wu
SR
,
Reddy
P.
Tissue tolerance: a distinct concept to control acute GVHD severity
.
Blood.
2017
;
129
(
13
):
1747
-
1752
.
6.
Jasperson
LK
,
Bucher
C
,
Panoskaltsis-Mortari
A
, et al
.
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
.
Blood.
2008
;
111
(
6
):
3257
-
3265
.
7.
Saha
A
,
Aoyama
K
,
Taylor
PA
, et al
.
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality
.
Blood.
2013
;
122
(
17
):
3062
-
3073
.
8.
Mohammadpour
H
,
Du
W
,
O’Neill
R
, et al
.
Host-derived serine protease inhibitor 6 provides granzyme B-independent protection of intestinal epithelial cells in murine graft-versus-host disease
.
Biol Blood Marrow Transplant.
2018
;
24
(
12
):
2397
-
2408
.
9.
Toubai
T
,
Tamaki
H
,
Peltier
DC
, et al
.
Mitochondrial deacetylase SIRT3 plays an important role in donor T cell responses after experimental allogeneic hematopoietic transplantation
.
J Immunol.
2018
;
201
(
11
):
3443
-
3455
.
10.
Karin
M
,
Clevers
H.
Reparative inflammation takes charge of tissue regeneration
.
Nature.
2016
;
529
(
7586
):
307
-
315
.
11.
Naik
S
,
Larsen
SB
,
Cowley
CJ
,
Fuchs
E.
Two to tango: dialog between immunity and stem cells in health and disease
.
Cell.
2018
;
175
(
4
):
908
-
920
.
12.
Sender
R
,
Milo
R.
The distribution of cellular turnover in the human body
.
Nat Med.
2021
;
27
(
1
):
45
-
48
.
13.
de Sousa E Melo
F
,
de Sauvage
FJ.
Cellular plasticity in intestinal homeostasis and disease
.
Cell Stem Cell.
2019
;
24
(
1
):
54
-
64
.
14.
Wells
JM
,
Watt
FM.
Diverse mechanisms for endogenous regeneration and repair in mammalian organs
.
Nature.
2018
;
557
(
7705
):
322
-
328
.
15.
Takahashi
S
,
Hashimoto
D
,
Hayase
E
, et al
.
Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
.
Blood.
2018
;
131
(
18
):
2074
-
2085
.
16.
Takashima
S
,
Kadowaki
M
,
Aoyama
K
, et al
.
The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells
.
J Exp Med.
2011
;
208
(
2
):
285
-
294
.
17.
Levine
JE
,
Huber
E
,
Hammer
ST
, et al
.
Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality
.
Blood.
2013
;
122
(
8
):
1505
-
1509
.
18.
Hummel
S
,
Ventura Ferreira
MS
,
Heudobler
D
, et al
.
Telomere shortening in enterocytes of patients with uncontrolled acute intestinal graft-versus-host disease
.
Blood.
2015
;
126
(
22
):
2518
-
2521
.
19.
Stüber
E
,
Von Freier
A
,
Marinescu
D
,
Fölsch
UR.
Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease
.
Gastroenterology.
1998
;
115
(
5
):
1205
-
1215
.
20.
Murphy
GF
,
Korngold
R.
Significance of selectively targeted apoptotic rete cells in graft-versus-host disease
.
Biol Blood Marrow Transplant.
2004
;
10
(
6
):
357
-
365
.
21.
Whitaker-Menezes
D
,
Jones
SC
,
Friedman
TM
,
Korngold
R
,
Murphy
GF.
An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression
.
Biol Blood Marrow Transplant.
2003
;
9
(
9
):
559
-
570
.
22.
Piguet
PF
,
Grau
GE
,
Allet
B
,
Vassalli
P.
Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
.
J Exp Med.
1987
;
166
(
5
):
1280
-
1289
.
23.
Fu
YY
,
Egorova
A
,
Sobieski
C
, et al
.
T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation
.
Immunity.
2019
;
51
(
1
):
90
-
103.e3
.
24.
Koyama
M
,
Mukhopadhyay
P
,
Schuster
IS
, et al
.
MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota
.
Immunity.
2019
;
51
(
5
):
885
-
898.e7
.
25.
Agudo
J
,
Park
ES
,
Rose
SA
, et al
.
Quiescent tissue stem cells evade immune surveillance
.
Immunity.
2018
;
48
(
2
):
271
-
285.e5
.
26.
Ferrara
JL
,
Smith
CM
,
Sheets
J
,
Reddy
P
,
Serody
JS.
Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis
.
J Clin Invest.
2017
;
127
(
7
):
2441
-
2451
.
27.
Hanash
AM
,
Dudakov
JA
,
Hua
G
, et al
.
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease
.
Immunity.
2012
;
37
(
2
):
339
-
350
.
28.
Zhu
P
,
Zhu
X
,
Wu
J
, et al
.
IL-13 secreted by ILC2s promotes the self-renewal of intestinal stem cells through circular RNA circPan3
.
Nat Immunol.
2019
;
20
(
2
):
183
-
194
.
29.
Ara
T
,
Hashimoto
D
,
Hayase
E
, et al
.
Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8
.
Sci Transl Med.
2020
;
12
(
550
):
eaaw0720
.
30.
Biton
M
,
Haber
AL
,
Rogel
N
, et al
.
T helper cell cytokines modulate intestinal stem cell renewal and differentiation
.
Cell.
2018
;
175
(
5
):
1307
-
1320.e22
.
31.
Bruce
DW
,
Stefanski
HE
,
Vincent
BG
, et al
.
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease
.
J Clin Invest.
2017
;
127
(
5
):
1813
-
1825
.
32.
Ratajczak
P
,
Janin
A
,
Peffault de Latour
R
, et al
.
Th17/Treg ratio in human graft-versus-host disease
.
Blood.
2010
;
116
(
7
):
1165
-
1171
.
33.
Sato
T
,
van Es
JH
,
Snippert
HJ
, et al
.
Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts
.
Nature.
2011
;
469
(
7330
):
415
-
418
.
34.
Norona
J
,
Apostolova
P
,
Schmidt
D
, et al
.
Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
.
Blood.
2020
;
136
(
12
):
1442
-
1455
.
35.
Hayase
E
,
Hashimoto
D
,
Nakamura
K
, et al
.
R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease
.
J Exp Med.
2017
;
214
(
12
):
3507
-
3518
.
36.
Yan
KS
,
Janda
CY
,
Chang
J
, et al
.
Non-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal
.
Nature.
2017
;
545
(
7653
):
238
-
242
.
37.
Ogasawara
R
,
Hashimoto
D
,
Kimura
S
, et al
.
Intestinal lymphatic endothelial cells produce R-Spondin3
.
Sci Rep.
2018
;
8
(
1
):
10719
.
38.
van Hoeven
V
,
Munneke
JM
,
Cornelissen
AS
, et al
.
Mesenchymal stromal cells stimulate the proliferation and IL-22 production of group 3 innate lymphoid cells
.
J Immunol.
2018
;
201
(
4
):
1165
-
1173
.
39.
Jagasia
M
,
Arora
M
,
Flowers
ME
, et al
.
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
.
Blood.
2012
;
119
(
1
):
296
-
307
.
40.
Nakasone
H
,
Fukuda
T
,
Kanda
J
, et al;
GVHD working group of the Japan Society of Hematopoietic Cell Transplantation
.
Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation
.
Bone Marrow Transplant.
2015
;
50
(
4
):
559
-
565
.
41.
Scott
BL
,
Pasquini
MC
,
Logan
BR
, et al
.
Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
.
J Clin Oncol.
2017
;
35
(
11
):
1154
-
1161
.
42.
Schörghuber
M
,
Fruhwald
S.
Effects of enteral nutrition on gastrointestinal function in patients who are critically ill
.
Lancet Gastroenterol Hepatol.
2018
;
3
(
4
):
281
-
287
.
43.
Feng
Y
,
McDunn
JE
,
Teitelbaum
DH.
Decreased phospho-Akt signaling in a mouse model of total parenteral nutrition: a potential mechanism for the development of intestinal mucosal atrophy
.
Am J Physiol Gastrointest Liver Physiol.
2010
;
298
(
6
):
G833
-
G841
.
44.
Feng
Y
,
Ralls
MW
,
Xiao
W
,
Miyasaka
E
,
Herman
RS
,
Teitelbaum
DH.
Loss of enteral nutrition in a mouse model results in intestinal epithelial barrier dysfunction
.
Ann N Y Acad Sci.
2012
;
1258
(
1
):
71
-
77
.
45.
Feng
Y
,
Teitelbaum
DH.
Epidermal growth factor/TNF-α transactivation modulates epithelial cell proliferation and apoptosis in a mouse model of parenteral nutrition
.
Am J Physiol Gastrointest Liver Physiol.
2012
;
302
(
2
):
G236
-
G249
.
46.
Feng
Y
,
Teitelbaum
DH.
Tumour necrosis factor--induced loss of intestinal barrier function requires TNFR1 and TNFR2 signalling in a mouse model of total parenteral nutrition
.
J Physiol.
2013
;
591
(
15
):
3709
-
3723
.
47.
Sun
X
,
Yang
H
,
Nose
K
, et al
.
Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function in a mouse model of total parenteral nutrition
.
Am J Physiol Gastrointest Liver Physiol.
2008
;
294
(
1
):
G139
-
G147
.
48.
Rafei
H
,
Jenq
RR.
Microbiome-intestine cross talk during acute graft-versus-host disease
.
Blood.
2020
;
136
(
4
):
401
-
409
.
49.
Lemal
R
,
Cabrespine
A
,
Pereira
B
, et al
.
Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? A study protocol for a randomized controlled trial (the NEPHA study)
.
Trials.
2015
;
16
(
1
):
136
.
50.
Fredricks
DN.
The gut microbiota and graft-versus-host disease
.
J Clin Invest.
2019
;
129
(
5
):
1808
-
1817
.
51.
Mathewson
ND
,
Jenq
R
,
Mathew
AV
, et al
.
Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
.
Nat Immunol.
2016
;
17
(
5
):
505
-
513
.
52.
Kaiko
GE
,
Ryu
SH
,
Koues
OI
, et al
.
The colonic crypt protects stem cells from microbiota-derived metabolites
.
Cell.
2016
;
167
(
4
):
1137
.
53.
Golob
JL
,
DeMeules
MM
,
Loeffelholz
T
, et al
.
Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD
.
Blood Adv.
2019
;
3
(
19
):
2866
-
2869
.
54.
Alam
A
,
Leoni
G
,
Quiros
M
, et al
.
The microenvironment of injured murine gut elicits a local pro-restitutive microbiota
.
Nat Microbiol.
2016
;
1
(
2
):
15021
.
55.
Jain
U
,
Ver Heul
AM
,
Xiong
S
, et al
.
Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice
.
Science.
2021
;
371
(
6534
):
1154
-
1159
.
56.
Ballegeer
M
,
Van Looveren
K
,
Timmermans
S
, et al
.
Glucocorticoid receptor dimers control intestinal STAT1 and TNF-induced inflammation in mice
.
J Clin Invest.
2018
;
128
(
8
):
3265
-
3279
.
57.
Fischer
A
,
Gluth
M
,
Weege
F
, et al
.
Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1
.
Am J Physiol Gastrointest Liver Physiol.
2014
;
306
(
3
):
G218
-
G228
.
58.
Seshadri
S
,
Pope
RL
,
Zenewicz
LA.
Glucocorticoids inhibit group 3 innate lymphocyte IL-22 production
.
J Immunol.
2018
;
201
(
4
):
1267
-
1274
.
59.
Jung
S
,
Fehr
S
,
Harder-d’Heureuse
J
,
Wiedenmann
B
,
Dignass
AU.
Corticosteroids impair intestinal epithelial wound repair mechanisms in vitro
.
Scand J Gastroenterol.
2001
;
36
(
9
):
963
-
970
.
60.
Takashima
S
,
Martin
ML
,
Jansen
SA
, et al
.
T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage
.
Sci Immunol.
2019
;
4
(
42
):
eaay8556
.
61.
Deng
Z
,
Lei
X
,
Zhang
X
, et al
.
mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration
.
J Mol Cell Biol.
2015
;
7
(
1
):
62
-
72
.
62.
Horsley
V
,
Aliprantis
AO
,
Polak
L
,
Glimcher
LH
,
Fuchs
E.
NFATc1 balances quiescence and proliferation of skin stem cells
.
Cell.
2008
;
132
(
2
):
299
-
310
.
63.
Meng
D
,
Frank
AR
,
Jewell
JL.
mTOR signaling in stem and progenitor cells
.
Development.
2018
;
145
(
1
):
dev152595
.
64.
Kinsella
S
,
Dudakov
JA.
When the damage is done: injury and repair in thymus function
.
Front Immunol.
2020
;
11
:
1745
.
65.
Velardi
E
,
Tsai
JJ
,
van den Brink
MRM.
T cell regeneration after immunological injury
.
Nat Rev Immunol.
2021
;
21
(
5
):
277
-
291
.
66.
Fletcher
AL
,
Acton
SE
,
Knoblich
K.
Lymph node fibroblastic reticular cells in health and disease
.
Nat Rev Immunol.
2015
;
15
(
6
):
350
-
361
.
67.
Hoggatt
J
,
Kfoury
Y
,
Scadden
DT.
Hematopoietic stem cell niche in health and disease
.
Annu Rev Pathol.
2016
;
11
(
1
):
555
-
581
.
68.
Wertheimer
T
,
Velardi
E
,
Tsai
J
, et al
.
Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration
.
Sci Immunol.
2018
;
3
(
19
):
eaal2736
.
69.
Dudakov
JA
,
Hanash
AM
,
Jenq
RR
, et al
.
Interleukin-22 drives endogenous thymic regeneration in mice
.
Science.
2012
;
336
(
6077
):
91
-
95
.
70.
Lopes
N
,
Vachon
H
,
Marie
J
,
Irla
M.
Administration of RANKL boosts thymic regeneration upon bone marrow transplantation
.
EMBO Mol Med.
2017
;
9
(
6
):
835
-
851
.
71.
Rossi
SW
,
Jeker
LT
,
Ueno
T
, et al
.
Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells
.
Blood.
2007
;
109
(
9
):
3803
-
3811
.
72.
Lucas
B
,
James
KD
,
Cosway
EJ
, et al
.
Lymphotoxin β receptor controls T cell progenitor entry to the thymus
.
J Immunol.
2016
;
197
(
7
):
2665
-
2672
.
73.
Severe
N
,
Karabacak
NM
,
Gustafsson
K
, et al
.
Stress-induced changes in bone marrow stromal cell populations revealed through single-cell protein expression mapping
.
Cell Stem Cell.
2019
;
25
(
4
):
570
-
583.e7
.
74.
Kaur
S
,
Raggatt
LJ
,
Millard
SM
, et al
.
Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment
.
Blood.
2018
;
132
(
7
):
735
-
749
.
75.
Camacho
V
,
Matkins
VR
,
Patel
SB
, et al
.
Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10
.
JCI Insight.
2020
;
5
(
22
):
e135681
.
76.
Golan
K
,
Singh
AK
,
Kollet
O
, et al
.
Bone marrow regeneration requires mitochondrial transfer from donor Cx43-expressing hematopoietic progenitors to stroma
.
Blood.
2020
;
136
(
23
):
2607
-
2619
.
77.
Onder
L
,
Narang
P
,
Scandella
E
, et al
.
IL-7-producing stromal cells are critical for lymph node remodeling
.
Blood.
2012
;
120
(
24
):
4675
-
4683
.
78.
Scandella
E
,
Bolinger
B
,
Lattmann
E
, et al
.
Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone
.
Nat Immunol.
2008
;
9
(
6
):
667
-
675
.
79.
Dertschnig
S
,
Nusspaumer
G
,
Ivanek
R
,
Hauri-Hohl
MM
,
Holländer
GA
,
Krenger
W.
Epithelial cytoprotection sustains ectopic expression of tissue-restricted antigens in the thymus during murine acute GVHD
.
Blood.
2013
;
122
(
5
):
837
-
841
.
80.
Dertschnig
S
,
Evans
P
,
Santos E Sousa
P
, et al
.
Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity
.
J Clin Invest.
2020
;
130
(
4
):
1896
-
1911
.
81.
Suenaga
F
,
Ueha
S
,
Abe
J
, et al
.
Loss of lymph node fibroblastic reticular cells and high endothelial cells is associated with humoral immunodeficiency in mouse graft-versus-host disease
.
J Immunol.
2015
;
194
(
1
):
398
-
406
.
82.
Kolupaev
OV
,
Dant
TA
,
Bommiasamy
H
, et al
.
Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD
.
Blood Adv.
2018
;
2
(
18
):
2307
-
2319
.
83.
Shono
Y
,
Ueha
S
,
Wang
Y
, et al
.
Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation
.
Blood.
2010
;
115
(
26
):
5401
-
5411
.
84.
Dudakov
JA
,
Mertelsmann
AM
,
O’Connor
MH
, et al
.
Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease
.
Blood.
2017
;
130
(
7
):
933
-
942
.
85.
Chen
L
,
Xiao
S
,
Manley
NR.
Foxn1 is required to maintain the postnatal thymic microenvironment in a dosage-sensitive manner
.
Blood.
2009
;
113
(
3
):
567
-
574
.
86.
Clave
E
,
Busson
M
,
Douay
C
, et al
.
Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation
.
Blood.
2009
;
113
(
25
):
6477
-
6484
.
87.
Fletcher
AL
,
Lowen
TE
,
Sakkal
S
, et al
.
Ablation and regeneration of tolerance-inducing medullary thymic epithelial cells after cyclosporine, cyclophosphamide, and dexamethasone treatment
.
J Immunol.
2009
;
183
(
2
):
823
-
831
.
88.
Zeng
M
,
Paiardini
M
,
Engram
JC
, et al
.
Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution
.
Blood.
2012
;
120
(
9
):
1856
-
1867
.
89.
Wynn
TA
,
Vannella
KM.
Macrophages in tissue repair, regeneration, and fibrosis
.
Immunity.
2016
;
44
(
3
):
450
-
462
.
90.
Guilliams
M
,
Svedberg
FR.
Does tissue imprinting restrict macrophage plasticity?
Nat Immunol.
2021
;
22
(
2
):
118
-
127
.
91.
Alexander
KA
,
Flynn
R
,
Lineburg
KE
, et al
.
CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease
.
J Clin Invest.
2014
;
124
(
10
):
4266
-
4280
.
92.
Taylor
DK
,
Mittereder
N
,
Kuta
E
, et al
.
T follicular helper-like cells contribute to skin fibrosis
.
Sci Transl Med.
2018
;
10
(
431
):
eaaf5307
.
93.
Yamakawa
T
,
Ohigashi
H
,
Hashimoto
D
, et al
.
Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease
.
Blood.
2018
;
131
(
13
):
1476
-
1485
.
94.
Du
J
,
Paz
K
,
Flynn
R
, et al
.
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production
.
Blood.
2017
;
129
(
18
):
2570
-
2580
.
95.
MacDonald
KP
,
Hill
GR
,
Blazar
BR.
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
.
Blood.
2017
;
129
(
1
):
13
-
21
.
96.
Henderson
NC
,
Rieder
F
,
Wynn
TA.
Fibrosis: from mechanisms to medicines
.
Nature.
2020
;
587
(
7835
):
555
-
566
.
97.
Ohigashi
H
,
Hashimoto
D
,
Hayase
E
, et al
.
Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD
.
Blood Adv.
2019
;
3
(
7
):
1003
-
1010
.
98.
Pakshir
P
,
Noskovicova
N
,
Lodyga
M
, et al
.
The myofibroblast at a glance
.
J Cell Sci.
2020
;
133
(
13
):
jcs227900
.
99.
Zhang
Y
,
Shen
L
,
Dreißigacker
K
, et al
.
Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease
.
Blood.
2021
;
137
(
17
):
2403
-
2416
.
100.
Adler
M
,
Mayo
A
,
Zhou
X
, et al
.
Principles of cell circuits for tissue repair and fibrosis
.
iScience.
2020
;
23
(
2
):
100841
.
101.
Flynn
R
,
Du
J
,
Veenstra
RG
, et al
.
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans
.
Blood.
2014
;
123
(
25
):
3988
-
3998
.
102.
Song
Q
,
Wang
X
,
Wu
X
, et al
.
IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice
.
Nat Commun.
2021
;
12
(
1
):
805
.
103.
Gartlan
KH
,
Bommiasamy
H
,
Paz
K
, et al
.
A critical role for donor-derived IL-22 in cutaneous chronic GVHD
.
Am J Transplant.
2018
;
18
(
4
):
810
-
820
.
104.
Banovic
T
,
MacDonald
KP
,
Morris
ES
, et al
.
TGF-beta in allogeneic stem cell transplantation: friend or foe?
Blood.
2005
;
106
(
6
):
2206
-
2214
.
105.
Volkmann
ER
,
Varga
J.
Emerging targets of disease-modifying therapy for systemic sclerosis
.
Nat Rev Rheumatol.
2019
;
15
(
4
):
208
-
224
.
106.
Jarman
EJ
,
Boulter
L.
Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair
.
Expert Opin Investig Drugs.
2020
;
29
(
2
):
179
-
190
.
107.
Dudakov
JA
,
Hanash
AM
,
van den Brink
MR.
Interleukin-22: immunobiology and pathology
.
Annu Rev Immunol.
2015
;
33
(
1
):
747
-
785
.
108.
Tang
KY
,
Lickliter
J
,
Huang
ZH
, et al
.
Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects
.
Cell Mol Immunol.
2019
;
16
(
5
):
473
-
482
.
109.
Krishnan
K
,
Arnone
B
,
Buchman
A.
Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing
.
Inflamm Bowel Dis.
2011
;
17
(
1
):
410
-
422
.
110.
Blazar
BR
,
Weisdorf
DJ
,
Defor
T
, et al
.
Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
.
Blood.
2006
;
108
(
9
):
3216
-
3222
.
111.
Coles
AJ
,
Azzopardi
L
,
Kousin-Ezewu
O
, et al
.
Keratinocyte growth factor impairs human thymic recovery from lymphopenia
.
JCI Insight.
2019
;
5
(
12
):
e125377
.
112.
Sémont
A
,
Mouiseddine
M
,
François
A
, et al
.
Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis
.
Cell Death Differ.
2010
;
17
(
6
):
952
-
961
.
113.
Voermans
C
,
Hazenberg
MD.
Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance
.
Blood.
2020
;
136
(
4
):
410
-
417
.
114.
Bloor
AJC
,
Patel
A
,
Griffin
JE
, et al
.
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study
.
Nat Med.
2020
;
26
(
11
):
1720
-
1725
.
115.
Sutherland
JS
,
Spyroglou
L
,
Muirhead
JL
, et al
.
Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade
.
Clin Cancer Res.
2008
;
14
(
4
):
1138
-
1149
.
116.
Perales
MA
,
Goldberg
JD
,
Yuan
J
, et al
.
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
.
Blood.
2012
;
120
(
24
):
4882
-
4891
.
117.
Tajima
A
,
Pradhan
I
,
Trucco
M
,
Fan
Y.
Restoration of thymus function with bioengineered thymus organoids
.
Curr Stem Cell Rep.
2016
;
2
(
2
):
128
-
139
.
118.
Shah
NJ
,
Mao
AS
,
Shih
TY
, et al
.
An injectable bone marrow-like scaffold enhances T cell immunity after hematopoietic stem cell transplantation
.
Nat Biotechnol.
2019
;
37
(
3
):
293
-
302
.
119.
Kreins
AY
,
Graham Davies
E.
Replacing defective thymus function
.
Curr Opin Allergy Clin Immunol.
2020
;
20
(
6
):
541
-
548
.
120.
Hashimoto
D
,
Chow
A
,
Greter
M
, et al
.
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
.
J Exp Med.
2011
;
208
(
5
):
1069
-
1082
.
121.
Flynn
R
,
Paz
K
,
Du
J
, et al
.
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism
.
Blood.
2016
;
127
(
17
):
2144
-
2154
.
122.
Cutler
CS
,
Lee
SJ
,
Arai
S
, et al
.
Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: The ROCKstar Study [published online ahead of print 15 July 2021]
.
Blood.
123.
Jagasia
M
,
Lazaryan
A
,
Bachier
CR
, et al
.
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
.
J Clin Oncol.
2021
;
39
(
17
):
1888
-
1898
.
124.
Zerr
P
,
Palumbo-Zerr
K
,
Distler
A
, et al
.
Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease
.
Blood.
2012
;
120
(
14
):
2909
-
2917
.
125.
DeFilipp
Z
,
Nazarian
RM
,
El-Jawahri
A
, et al
.
Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease
.
Blood Adv.
2017
;
1
(
22
):
1919
-
1922
.
Sign in via your Institution